

Collaboration Agreement (may alternatively be referred to as "Sponsorship Agreement" or "Head Collaboration Agreement")

(the "Agreement")

1. Parties

BY AND BETWEEN:

SANOFI-AVENTIS DENMARK A/S, a company duly registered under the laws of Denmark under the trade number 19064301 and having its registered office at Slotsmarken 13 DK- 2970 Hørsholm, represented by Charlotte Vestergaard, General Manager, **Sanofi Genzyme**, hereinafter the "Company"

and

Atopisk Eksem Forening, a non-profit organisation having its registered office at Dådyrvænget 504, 2980 Kokkedat, represented by Anne Skov Vacstrup as Formand, hereinafter the "Organisation" Ansterdamhusene 32,3600 Frederics and

hereinafter referred to individually as "Party" and jointly as the "Parties"

have agreed to collaborate as follows.

2. Purpose of the Agreement

The purpose of this Agreement between the Parties shall be to give financial support to a update of homepage and Facebook group.

3. Name of the collaborative project

The name of the collaborative project shall be Atopisk Eksem Forening – update of homepage and Facebook group.

4. Roles of the collaborating Parties

- 4.1 The Company shall undertake during the term of the Agreement to sponsor part of the costs for the above project.
- 4.2 The Organisation undertakes during the term of this Agreement to update the homepage and Facebook group.



5. Timescale

This Agreement, the purpose and scope of which are described in Articles 2 and 4 shall run from date of signature to May 25th, 2018.

The rights and obligations of the Parties under this Agreement shall run from date of signature and unless otherwise expressly agreed, until the obligations of the Agreement shall have been fully fulfilled.

6. Financial commitment

The Company's financial commitment under this Agreement shall be in the sum of Two hundred and sixty eight thousand seven hundred and fifty Danish kroner (DKK 268,750.-), including VAT, and shall be used for the above project.

7. Non-financial commitment

The Company's non-financial commitment shall be none.

8. Disclosure

This Agreement shall be publicly disclosed on the Company's website until 6 months' after signature.

9. Independence and conflict of interest

The Parties declare in signing this Agreement that the Organisation shall be free to collaborate with several pharmaceutical companies and that the Company shall be free to collaborate with one or more organisations. The Parties further state that their relations shall not involve exclusive rights with respect to specific product or therapeutic areas.

The Company agrees in signing this Agreement not to impose conditions for the Organisation's professional or stakeholder-policy viewpoints.

The Company agrees in signing this Agreement that it has no executive duties in the Organisation that have any significance for the present Agreement.

10. Breach of Agreement

If one of the Parties is in breach of its obligations under this Agreement, the other Party may terminate the Agreement with immediate effect and the latter Party shall be entitled to seek other legal redress in Danish law for breach of agreement, including a claim for compensation irrespective of whether the Agreement shall have been terminated.



11. Law

This Agreement shall be subject in every respect to Danish law.

12. Dispute resolution

Any disputes arising between the Parties in connection with the interpretation, validity, performance or termination hereof which cannot be resolved by mediation, shall be brought before the Maritime and Commercial Court in Copenhagen.

13. Signatures

IN WITNESS WHEREOF, Organisation and the Company hereto, intending to be bound hereby, have caused this Agreement to be duly executed in two (2) originals as of the Effective Date.

ORGANISATION

Date: 27.01.20B

Name: PANNE SKOV VASTRUP

Title: CHAIRMAN

Signature: Ane Ska Vostry

ORGANISATION

Date: 27.1.2018

Name: Villiam Faber

Title: Member

Signature:

COMPANY

Date: Jan 19, 2018

Name: Charlotte Vestergaard

Sanofi Genzyme

Title: General Manager

Signature:

charlotte Vestergaard (Jan 19, 2018)